Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents

Stopped early · Phase 3

Conditions studied: Diabetes Mellitus, Type 1

In brief

To assess the safety and efficacy of Exubera on pulmonary function and glycemic control in subjects ages 6-17 over a 1 year period.

Key facts

Study ID

NCT00479258

Run by

Pfizer

People needed

2

Starts

2007-10-01

Expected to finish

2007-10-01

Last updated by the study team

2018-10-01

Who can join

Age: 6 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with Type 1 diabetes mellitus for more than 6 months.
• Males and females ages 6 to 17 years.
• Subjects should be receiving, or be able to tolerate, at a minimum a 3 unit pre prandial dose of short acting subcutaneous insulin.

You may not qualify if…

• Subjects using an insulin pump
• Smoking

Where it is running

• Pfizer Investigational Site — Buffalo, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.